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Health care utilization history, GOLD guidelines, 
and respiratory medication prescriptions  
in patients with COPD
Background: The relationship between prior health care utilization and respiratory medication 
prescriptions in an unselected population of patients with COPD is not known.
Methods: We determined the prescribed respiratory medications and respiratory and nonres-
piratory health care encounters in 523 Veterans with COPD at the Cincinnati Veterans Affairs 
Medical Center between 2000 and 2005. Prescribed treatments were compared with the GOLD 
guidelines and each patient was classified as receiving less medications than recommended in 
the guidelines (G), medications according to the guidelines (=G), or more medications than 
recommended (G).
Results: Respiratory medications were G for 54%, =G in 33%, and G for 14% of the 
patients studied. For GOLD stages 1 and 2, G patients had the fewest and G patients the 
most prior respiratory encounters during a 12 month period (0.31 ± 0.073 (0.21, 0.47), 0.75 ± 
0.5 (0.37, 1.5), 1.1 ± 0.27 (0.74, 1.6) visits/person/year, G, =G, G, respectively, mean + 
standard error of mean (SEM) (95% confidence limits) 2 degrees of freedom (df) ANOVA   
P  0.001 for prescription effect). For GOLD stages 3 and 4, G was associated with sig-
nificantly fewer prior respiratory visits than was =G (0.78 ± 0.11 (0.6, 1.0) and 2.4 ± 0.47 (1.9, 3.1)   
visits/person/year, respectively, P  0.001). There were no differences in nonrespiratory health 
care visits for GOLD stages 1 and 2 by prescription level (3.1 ± 0.24 (2.6, 3.5), 3.1 ± 0.46 (2.1, 
4.6) and 4.1 ± 0.55 (3.3, 5.1) visits/person/year, G, =G, G respectively, 2 df ANOVA P = 
0.096) or for GOLD stages 3 and 4 (3.6 ± 0.25 (3.2, 4.1) and 4.0 ± 0.44 (3.3, 4.9) visits/ per-
son/year, G and =G, respectively, P = 0.36).
Conclusions: Respiratory medications prescribed for an unselected population with a broad 
range of COPD severity complied poorly with the GOLD pharmacologic treatment guidelines 
but correlated with the number of prior respiratory health care visits.
Keywords: health care, COPD, respiratory visits, GOLD guidelines, prescription
Introduction
Chronic obstructive pulmonary disease (COPD) is a common disease affecting 12–24 
million adults in the United States.1,2 COPD is currently the fourth leading cause of 
mortality and is projected to be the third leading cause of death by 2020.1,2 Outpatient 
health care encounters, emergency department visits, and hospitalizations prompted 
by COPD cost more than 32 billion dollars yearly.1,2
Over 50 clinical practice guidelines have been developed for the management of 
COPD.3,4 The Global Strategy for the Diagnosis and Management of Chronic Obstructive 
Lung Disease (GOLD), a collaboration of the World Health Organization and the National 
Heart Lung and Blood Institute of the National Institute of Health, has created evidence-
based guidelines with standards for grading evidence, explicit recommendations, and a 
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well organized implementation group with regular, systematic 
updates and revisions.5 Nevertheless, despite international dis-
semination and intensive promotion, the GOLD guidelines have 
not been universally adopted and implemented by primary care 
physicians or pulmonologists.6–13
The reasons for poor adherence with COPD treatment 
guidelines are not well understood. Potential factors contrib-
uting to noncompliance include low utilization of spirometry, 
unawareness of guideline recommendations, and perceived 
ineffectiveness.14 To examine the relationship between prior 
health care utilization and the prescription of respiratory 
medications, we determined respiratory health care encoun-
ters and the prescription of respiratory medications compared 
with the GOLD guidelines in an unselected population with 
COPD.
Patients and methods
Patients
We reviewed, retrospectively, the medical records of all patients 
at the Cincinnati Veterans Administration Medical Center 
(VAMC)with a diagnosis of COPD between June 1, 2000 and 
June 1, 2005 (Figure 1). To ensure that all participants were 
followed actively, individuals who did not have at least one 
health care encounter in the 12 months prior to the study were 
excluded (n = 189, Figure 1). Prescribed therapeutic regimens 
compared with GOLD treatment guidelines are presented in 
Figure 1. All spirometry was performed in the Cincinnati 
VAMC Pulmonary Function Laboratory according to Ameri-
can Thoracic Society (ATS) guidelines. For 131 patients, the 
forced expiratory volume in 1 second (FEV1) divided by the 
forced vital capacity (FVC), FEV1/FVC, was 0.70 and they 
were classified as clinical COPD (former GOLD stage 0).5 
The remaining 392 patients were classified into 4 stages 
(modified GOLD 1, modified GOLD 2, modified GOLD 3, 
modified GOLD 4) defined by the GOLD guidelines based 
upon prebronchodilator spirometry.5
Study design
Each patient’s prescribed medication regimen was compared 
with the GOLD treatment guidelines. Subjects were classified 
as less medications than guidelines (G) if they were pre-
scribed less than the recommended regimen, according to 
guidelines (=G) if their respiratory medication prescription 
met the guidelines, and more medications than guidelines 
(G) if they were prescribed more respiratory medications 
than recommended. The Veterans Affairs medical system 
electronic medical record was reviewed and every outpatient 
visit, emergency department encounter, and hospitalization 
during the preceding 60 months was categorized as respiratory 
or nonrespiratory based upon the chief complaint and diag-
nostic coding for the encounter. Examples of respiratory chief 
complaints included breathlessness, cough, or wheezing.
Because the prescription record could be determined most 
accurately at the time of the chart review, the primary analy-
sis studied health care encounters during the preceding 
12 months. In a secondary analysis, we extended the time 
frame to the preceding 60 months.
This protocol was approved by the Research and 
  Development Committee of the Cincinnati VAMC and the 
University of Cincinnati Institutional Review Board. The 
need for consent was waived.
Statistics
The analyses of health care visits were conducted on the 
counts of encounters over 12 months and 60 months. Based 
upon the inclusion criteria, all patients were assumed to have 
been followed actively throughout the 60 month period. Only 
health care encounters that occurred within the Cincinnati 
VAMC system were counted and any period with no entry 
in the electronic medical record was recorded as zero visits 
for that time span. All visit frequencies were normalized to 
yearly rates. For many analyses, modified GOLD groups 
1 and 2 were pooled, as were groups 3 and 4, because the 
combined modified GOLD groups shared similar physiologic 
characteristics and treatment recommendations.4 Patients 
with clinical COPD could be categorized as =G or G. 
Patients in modified GOLD stage 1 and 2 could be classified 
as G, =G, or G, whereas modified GOLD 3 and 4 subjects 
were grouped as G or =G.
For all analyses in which the number of visits was the 
dependent variable, confidence limits and P-values were 
based upon Wald tests within Poisson models with the Pois-
son variance estimates adjusted by the ratio of the model 
deviance to the model degrees of freedom. The study alpha 
was P = 0.05, two-tailed. Results are presented as mean ± 
SEM (upper and lower 95% confidence limits).
Results
Study population
1338 patient records were evaluated and 523 patients were 
studied (Figure 1). The clinical characteristics of the study 
population are presented in Tables 1 and 2.
Health care visits
Hospital, emergency department (ED), outpatient respiratory 
and nonrespiratory visits over the 12 and 60 month periods International Journal of COPD 2010:5 91
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are shown in Figure 2. ED and outpatient visits comprised 
similar proportions of total respiratory visits (35% and 48%) 
whereas there were 6-fold more outpatient visits (83%) than 
ED visits (12%–13%) for nonrespiratory causes. Hospitaliza-
tions represented 16%–17% of respiratory visits but only 
4%–5% of nonrespiratory encounters. The number of hos-
pital, ED, and outpatient respiratory visits increased with 
each modified GOLD stage, whereas the number of nonres-
piratory visits/person/year was similar for all groups over the 
12 month period. Respiratory and nonrespiratory visits over 
the 60 month period are presented in Figure 3.
The annualized frequency of prior respiratory encounters 
is presented in Figure 4. In the 12 month period, the majority 
of the patients (81%) had 3 or fewer respiratory encounters; 
80.7% of all respiratory encounters occurred in 17.5% of the 
patients. In contrast, approximately two-thirds of patients 
(70%) had a respiratory encounter during the 60 month period. 
Approximately half of the patients (53.4%) had 1–5 respira-
tory encounters accounting for 39.7% of respiratory visits 
whereas 16.6% of patients had more than 5 encounters and 
accounted for 60.3% of all respiratory visits.
Prior health care encounters and 
respiratory medication prescriptions
In the clinical COPD group (former GOLD 0), patients 
receiving G had twice as many prior respiratory visits as 
patients receiving =G, 0.58 ± 0.19 versus 0.27 ± 0.057 visits/
person/year, P = 0.02. (Table 3) This increased total health 
care utilization was caused by more ED visits and hospital-
izations. In the composite group modified GOLD 1 and 2, 
the prescription level increased as the number of prior 
  respiratory event related encounters rose (2 df ANOVA   
P  0.0001, Table 3). There were no significant differences 
in total nonrespiratory visits (2 df ANOVA P = 0.096, Table 3). 
In the composite group modified GOLD 3 and 4, those indi-
viduals receiving = G had three times as many total respiratory 
visits as those who received  G, P  0.0001 (Table 3). This 
increase was due to elevated numbers of office visits as well 
as ED encounters and hospitalizations. There were no 
  differences in hospital, office, or total nonrespiratory visits, 
P = 0.36. Similar relationships between prescribed treatment 
and respiratory and nonrespiratory encounters were present 
during the 60 month period (Table 3).
Discussion
Respiratory medications prescribed for patients in this 
unselected population with a broad range of air flow limita-
tion and COPD severity complied poorly with the GOLD 
Patients with 
diagnosis of COPD 
at Cincinnati
VAMC (n = 1338)    
Pulmonary function 
testing (n = 523) 
Patients stratified according
to modified GOLD criteria 
Compare
actual prescriptions
with GOLD guidelines
Less prescriptions
than guidelines 
(<G) n = 280(54%)
More prescriptions 
than guidelines 
(>G) n = 73(14%) 
Prescriptions 
per guidelines 
(=G) n = 170(33%) 
– 
– 
– 
– 
– 
Excluded: n = 815 
No PFT’s on file, n = 174 
PFT’s > 5 years prior to data 
collection, n = 45 
Deceased, n = 353 
Concurrent diagnosis of 
asthma, n = 54 
No health care encounter in 
the 12 months prior to data 
collection, n = 189 
Assess office, 
emergency department, 
hospital visits due to respiratory 
or nonrespiratory causes
Figure 1 Flow diagram for inclusion and exclusion of study patients.
Note: The diagnosis of COPD was defined by ICD-9 codes, 491.XX (Chronic Bron-
chitis), 492.XX (Emphysema) and 496.XX (Chronic Obstructive Lung Disease).
Table 1 Characteristics of the 523 study subjects
Gender
Male 498 (95%)
Female 25 (5%)
Age (years) 66.5 ± 11.0
Race
White 444 (85%)
African-American 68 (13%)
Asian 1 (0.2%)
Other/not noted 10 (2%)
Spirometry
within 2 years 321 (61%)
within 5 years 523 (100%)
Smoking status
current smoker 257 (50%)
former smoker 245 (47%)
never smoker 17 (3%)
Medications
Short acting beta agonist 346 (66%)
Long acting beta agonist 114 (22%)
Ipratroprium 181 (35%)
Albuteral/Ipratroprium
(Combivent®) 114 (22%)
Theophylline 46 (9%)
Tiotroprium 10 (2%)
Inhaled steroid 158 (30%)
Systemic steroid 31 (6%)
Supplemental oxygen 121 (23%)
Notes: Age is mean ± SD; all others are n (%).International Journal of COPD 2010:5 92
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guidelines for the pharmacologic management of COPD. 
Over half the patients were prescribed less than the recom-
mended respiratory medications. A prior history of reduced 
numbers of respiratory health care encounters was associated 
with less than guideline recommended prescription of respi-
ratory medications for all levels of COPD severity. The 
number of respiratory related health care visits per person   
per year increased significantly with progressively more 
severe modified GOLD stage whereas the annual number of 
nonrespiratory health care visits was similar for individuals 
in all stages suggesting that these differences were not related 
to access to care or global health care utilization patterns.
Despite extensive publicity and promotion, clinical prac-
tice guidelines for the management of COPD have been poorly 
adopted by primary care practitioners and pulmonologists.6–13 
Table 2 Distribution of patients, FEV1, and FEV1/FVC according to 
modified GOLD stage
Modified  
GOLD stage
n (%) FEV1 (l) FEV1/FVC (%)
Clinical 131 (25%) 2.47 ± 0.71 
(2.35 - 2.59)
77.2 ± 5.69 
(76.27 - 78.22)
COPD
1 28 (5%) 2.66 ± 0.61 
(2.44 - 2.88)
65.1 ± 3.17 
(63.89 - 66.25)
2 134 (25.6%) 2.03 ± 0.50 
(1.94 - 2.11)
58.8 ± 6.57 
(57.63 - 59.86)
3 113 (21.6%) 1.29 ± 0.32 
(1.23 - 1.35)
47.9 ± 8.92 
(46.2 - 49.49)
4 117 (22.4%) 0.89 ± 0.28 
(0.84 - 0.94)
42.3 ± 9.31 
(40.63 - 44)
Notes: Results are mean ± SEM (95% confidence intervals).
Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
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Figure 2 Distribution of health care encounters over 12 and 60 month intervals.
Notes: Results are mean ± SEM. Panel A shows hospital, ED, outpatient, and total respiratory visits. Panel B shows hospital, ED, outpatient, and total nonrespiratory visits.
Abbreviations: Hospital, hospitalizations; ED, emergency department visits; Outpatient, outpatient health care encounters;   All, total health care encounters.
The COPD Resource Network Needs Assessment Survey 
found that although 54% of generalists and 94% of pulmon-
ologists were aware of published COPD guidelines, they often 
under-prescribed recommended pharmacologic treatments.8 
We found that 54% of patients were prescribed less medica-
tions than recommended. Although unawareness of COPD 
guidelines may be one factor contributing to the lack of adher-
ence, independent prescribing habits and absence of apparent 
effect on patient outcomes may also influence physician 
utilization of practice guidelines.15 A history of fewer respira-
tory encounters correlated with less than recommended pre-
scription of respiratory medications suggesting that providers 
and possibly patients perceived less need for these treatments. 
Conversely, our findings indicate that physicians prescribe 
more than recommended medications for patients who have 
more frequent respiratory health care encounters. Thus, prior 
health care visits for respiratory symptoms may influence 
caregivers to prescribe more respiratory treatments in an effort 
to alleviate symptoms and improve respiratory health regardless 
of a patient’s lung function measured by spirometry. Similarly, 
the Resource Use Study in COPD demonstrated that patients 
experiencing COPD exacerbations were prescribed signifi-
cantly more medications than those who did not have respira-
tory symptoms.16
In our unselected population, most health care encoun-
ters for COPD were confined to a small fraction of 
patients with COPD and this population may be dispro-
portionately represented in some studies of respiratory 
medications.17 The results of these studies provide, in 
part, the evidence for spirometry-based COPD manage-
ment guidelines and may, potentially, bias recommenda-
tions toward more treatment. Increased health care International Journal of COPD 2010:5 93
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Figure 3 Health care encounters during the 12 month period (A, B) and the 60 month period (C, D) according to modified GOLD stage.
Notes: Results are mean ± SEM (95% confidence interval). Panel A shows hospital, ED, outpatient, and total respiratory visits. Patients with advanced COPD had more respi-
ratory health care visits compared with individuals with a clinical diagnosis of COPD (0.36 ± 0.067 (0.24, 0.54), 0.29 ± 0.15 (0.11, 0.77), 0.58 ± 0.11 (0.42, 0.80), 1.0 ± 0.23 (0.77, 1.3), 
and 1.4 ± 0.19 (1.1, 1.7) visits/person/year over the 12 month period for clinical COPD (former GOLD stage 0) and modified GOLD stages 1, 2, 3, and 4 respectively, 4 df 
ANOVA P  0.001). Panel B shows hospital, ED, outpatient, and total nonrespiratory visits. The frequency of nonrespiratory health care visits was the same in all groups 
regardless of modified GOLD stage (3.8  ±  0.24 (3.4, 4.3), 3.2 ± 0.39 (2.4, 4.3), 3.3 ± 0.24 (2.9, 3.8), 3.6 ± 0.46 (3.1, 4.1), and 3.8 ± 0.31 (3.3, 4.3) visits/person/year for clinical 
COPD and modified GOLD stages 1, 2, 3, and 4 respectively, 4 df ANOVA P = 0.51). Panel C shows the number of office, ED, and hospital respiratory visits increasing with 
each modified GOLD stage from 0.34 ± 0.032 visits/person/year in patients with a clinical diagnosis of COPD to 1.1 ± 0.13 visits/person/year for those individuals in modified 
GOLD stage 4 (4df ANOVA comparing all groups, P  0.001). Panel D shows similar numbers of hospital, ED, office, and total nonrespiratory visits in each modified GOLD 
stage, 4df ANOVA comparing all groups P = 0.45).
utilization may be a distinguishing clinical characteristic 
that differentiates a phenotypically distinct group of 
individuals with COPD.18 Our results suggest that studies 
including only individuals with prior respiratory health 
care encounters may not be applicable to a general, 
unselected COPD population and may provide a partial 
explanation for the apparent less than recommended 
prescription of respiratory medications.19
There is a paucity of available data to demonstrate that 
COPD treatment guidelines reduce health care utilization by 
individuals with COPD or affect mortality.20 An observational 
study comparing patients managed in general practices 
according to the British Thoracic Society guidelines or usual 
care found no differences in general practitioner or nurse 
visits, outpatient referrals, or hospitalizations.21 Similarly, 
we did not see fewer prior health care encounters in patients 
prescribed respiratory medications per guideline recommen-
dations. In fact, for the entire cohort over 12 months, more 
total respiratory visits occurred in those receiving = G than 
for those who received G or G (0.6 ± 0.071(0.48, 0.75), 
1.06 ± 0.19(0.85, 1.3), and 0.84 ± 0.17(0.58, 1.2) visits/
person/year, for G, =G, and G, respectively (2 df ANOVA 
P = 0.002). However, this study’s methodology did not allow 
us to determine whether this effect was caused by prescription 
of fewer respiratory medications for less symptomatic 
patients and prescription of increased treatments for more 
symptomatic patients regardless of their pulmonary function 
or whether step-wise pharmacologic management strategy International Journal of COPD 2010:5 94
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Figure 4 Frequency of yearly health care respiratory health care encounters per 
person during the 12 and 60 month periods.
based upon spirometry does not reduce respiratory health 
care encounters.
A systematic review to develop clinical practice guidelines 
for the diagnosis and management of stable COPD revealed 
insufficient evidence to support using spirometry to guide 
therapy.22,23 Furthermore, spirometry is not an effective guide 
for the management of patients with COPD and frequent 
exacerbations.24 The BODE index, a score based upon FEV1, 
6 minute walk test, level of dyspnea, and body mass index, 
predicts mortality, hospitalization, and COPD exacerbation 
frequency and severity better than FEV1 alone.25,26 Analysis 
of patients enrolled in the National Emphysema Treatment 
Trial suggests that multifactorial models incorporating 
physiologic parameters, breathlessness, prior exacerbations, 
and comorbidities may prognosticate emergency department 
visits or hospitalizations.27 It is not yet known whether these 
factors or a multivariable index that includes prior respiratory 
health care visits can be used to guide the pharmacologic 
management of individuals with COPD.
The frequency of respiratory health care visits by indi-
viduals with COPD increased as the FEV1 declined and the 
modified GOLD stage increased whereas the number of 
nonrespiratory visits was the same regardless of GOLD stage. 
Although other investigators have demonstrated that the 
number of COPD exacerbations increases as the FEV1 
decreases, the relationship between spirometry and exacerba-
tion frequency is not consistent.24,28–34 Others have shown that 
multivariable indices such as the BODE index alone or com-
bined with other parameters predict COPD exacerbations.27,35 
However, these studies are difficult to compare because the 
clinical characteristics of the studied populations varied 
greatly as did the definitions of COPD exacerbation. In our 
population of unselected patients with a broad range of 
disease severity, the frequency of respiratory health care 
encounters increased as FEV1 declined.
In this study, we utilized only the Veterans Affairs medi-
cal record system and may have underestimated total health 
care utilization by omitting any encounters that occurred 
outside of the Veterans Health care Administration (VHA). 
Approximately 30%–40% of health care encounters occurred 
outside the VHA in a multicenter trial evaluating COPD 
medications based in Veteran Affairs medical centers.17 We 
required that all subjects have at least one encounter in the 
prior year to insure that they were actively receiving care at 
the Cincinnati VAMC and our results were similar for both 
the 12 and 60 month time periods suggesting stable respira-
tory health care utilization within our cohort. Furthermore 
the data within the electronic medical records available for 
our review was the same information that was available to 
the prescribing caregiver so it is representative of the clinical 
data upon which respiratory medications were prescribed.
Although our results are comparable to findings from 
other VAMC14,17 the findings of this study are restricted to a 
predominantly male population from a single medical center 
and will require validation in a larger, more diverse popula-
tion of individuals with COPD. We used the pre-bronchodi-
lator FEV1 rather than the post-bronchodilator FEV1 to 
classify patients according to the modified GOLD guidelines 
because the majority of patients had not undergone broncho-
dilator testing. We did not assess compliance with the pre-
scribed medication regimen so it is possible that differences 
in patients’ adherence with their medications within the 
various GOLD defined groups might have contributed to the 
different rates of respiratory health care encounters and, 
possibly, to the prescription of more respiratory medications. 
Future prospective trials will be necessary to assess these 
factors.
This study demonstrates that respiratory medications 
prescribed for an unselected population of individuals with 
COPD of diverse severity complied poorly with the GOLD 
treatment guidelines. The majority of patients were pre-
scribed fewer medications than recommended and these 
patients had fewer prior respiratory health care visits. 
  Prescription of more than the recommended respiratory 
medications correlated with a history of increased frequency 
of respiratory health care encounters suggesting that more 
respiratory medications are prescribed for patients with 
increased health care utilization regardless of their lung 
function measured by spirometry. In addition, the majority 
of respiratory health care encounters occurred in a minor-International Journal of COPD 2010:5 95
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ity of patients and these phenotypically distinct patients 
may be over-represented in some studies of respiratory 
medications that provide, in part, the evidence for spirom-
etry-based COPD treatment guidelines, potentially biasing 
recommendations toward increased prescription of respira-
tory medications. Prior respiratory-related health care 
encounters may provide a measure of a patient’s respiratory 
symptoms and may be an important factor influencing 
caregiver prescription of respiratory medications. In an 
unselected population with COPD, both a history of fewer 
respiratory health care encounters in an individual patient 
and guidelines based upon studies of patients with increased 
respiratory health care utilization may provide potential 
explanations for the prescription of less than recommended 
respiratory medications compared with the spirometry-
based GOLD guidelines.
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